Scribe Therapeutics Inc. Common Stock (SCTX) — Working Capital to Net Assets Ratio
Scribe Therapeutics Inc. Common Stock (SCTX) has a Working Capital to Net Assets ratio of 20.4% as of June 2026. Working capital of $-33.59 Million (current assets of $45.10 Million minus current liabilities of $78.70 Million) is measured against net assets of $-164.85 Million. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Scribe Therapeutics Inc. Common Stock Working Capital to Net Assets (2024–2025)
This chart shows how Scribe Therapeutics Inc. Common Stock's Working Capital to Net Assets ratio has evolved across 2 annual periods from 2024 to 2025. As of June 2026, the ratio stands at 20.4%, reflecting working capital of $-33.59 Million against net assets of $-164.85 Million USD. See Scribe Therapeutics Inc. Common Stock defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Scribe Therapeutics Inc. Common Stock (2024–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Scribe Therapeutics Inc. Common Stock from 2024 to 2025, covering 2 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see how large is Scribe Therapeutics Inc. Common Stock's balance sheet.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 1.5% | $-2.12 Million | $-143.42 Million | $66.93 Million | $69.06 Million | ▲ +61.4 pp |
| 2024 | -59.9% | $75.36 Million | $-125.86 Million | $110.37 Million | $35.02 Million | — |